In Vitro Activity of the Arylaminoartemisinin GC012 against Helicobacter pylori and Its Effects on Biofilm

This study evaluated the in vitro activity of the arylaminoartemisinin GC012, readily obtained from dihydroartemisinin (DHA), against clinical strains of Helicobacter pylori (H. pylori) with different antibiotic susceptibilities in the planktonic and sessile state. The activity was assessed in terms of bacteriostatic and bactericidal potential. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined by the broth microdilution method. After treatment with GC012, all bacterial strains showed significantly lower MIC and MBC values compared to those of DHA. The effect of combination of GC012 with antibiotics was examined using the checkerboard method. GC012 displayed synergistic interactions with metronidazole, clarithromycin, and amoxicillin in all the strains. The antibiofilm activity was evaluated via crystal violet staining, AlamarBlue® assay, colony-forming unit count, and fluorescence microscopy. At ½ MIC and ¼ MIC concentration, both GC012 and DHA inhibited biofilm formation, but only GC012 showed a minimal biofilm eradication concentration (MBEC) on mature biofilm. Furthermore, both compounds induced structural changes in the bacterial membrane, as observed by transmission electron microscopy (TEM) and scanning electron microscopy (SEM). It is thereby demonstrated that GC012 has the potential to be efficacious against H. pylori infection.

[1]  S. Carradori,et al.  Selective Inhibition of Helicobacter pylori Carbonic Anhydrases by Carvacrol and Thymol Could Impair Biofilm Production and the Release of Outer Membrane Vesicles , 2021, International journal of molecular sciences.

[2]  K. Baek,et al.  Therapeutic Promises of Medicinal Plants in Bangladesh and Their Bioactive Compounds against Ulcers and Inflammatory Diseases , 2021, Plants.

[3]  P. Sun,et al.  Recent pharmacological advances in the repurposing of artemisinin drugs , 2021, Medicinal research reviews.

[4]  L. Wiesner,et al.  Toward New Transmission-Blocking Combination Therapies: Pharmacokinetics of 10-Amino-Artemisinins and 11-Aza-Artemisinin and Comparison with Dihydroartemisinin and Artemether , 2021, Antimicrobial agents and chemotherapy.

[5]  R. Bye,et al.  Anti-Helicobacter pylori Activity of Artemisia ludoviciana subsp. mexicana and Two of Its Bioactive Components, Estafiatin and Eupatilin , 2021, Molecules.

[6]  Y. Yamaoka,et al.  Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications , 2021, Nature Reviews Gastroenterology & Hepatology.

[7]  R. Grande,et al.  Biofilm Formation as a Complex Result of Virulence and Adaptive Responses of Helicobacter pylori , 2020, Pathogens.

[8]  S. Carradori,et al.  Synthesis and Biological Evaluation of Carvacrol-Based Derivatives as Dual Inhibitors of H. pylori Strains and AGS Cell Proliferation , 2020, Pharmaceuticals.

[9]  D. Baker.  Plants against Helicobacter pylori to combat resistance: An ethnopharmacological review , 2020, Biotechnology reports.

[10]  I. Korona-Głowniak,et al.  The In Vitro Activity of Essential Oils against Helicobacter Pylori Growth and Urease Activity , 2020, Molecules.

[11]  S. Chaudhary,et al.  Artemisinin‐derived antimalarial endoperoxides from bench‐side to bed‐side: Chronological advancements and future challenges , 2020, Medicinal research reviews.

[12]  P. Ferrante,et al.  The Use of Antimalarial Drugs against Viral Infection , 2020, Microorganisms.

[13]  E. Winzeler,et al.  Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapies–Activities Against Blood Stage P. falciparum Including PfKI3 C580Y Mutants and Liver Stage P. berghei Parasites , 2020, Frontiers in Chemistry.

[14]  S. Carradori,et al.  Identification and characterization of the α-CA in the outer membrane vesicles produced by Helicobacter pylori , 2019, Journal of enzyme inhibition and medicinal chemistry.

[15]  Hidekazu Suzuki,et al.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker , 2019, Journal of neurogastroenterology and motility.

[16]  Qingjie Zhao,et al.  Biological Activities of Artemisinin Derivatives Beyond Malaria. , 2019, Current topics in medicinal chemistry.

[17]  S. Carradori,et al.  Chromatographic Analyses, In Vitro Biological Activities, and Cytotoxicity of Cannabis sativa L. Essential Oil: A Multidisciplinary Study , 2018, Molecules.

[18]  D. Graham,et al.  Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. , 2018, Gastroenterology.

[19]  K. Ottemann,et al.  Helicobacter pylori Biofilm Involves a Multigene Stress-Biased Response, Including a Structural Role for Flagella , 2018, mBio.

[20]  M. Leja,et al.  Epidemiology of Helicobacter pylori infection , 2018, Helicobacter.

[21]  Y. Yamaoka.  Faculty Opinions recommendation of Review article: the global emergence of Helicobacter pylori antibiotic resistance. , 2018, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[22]  Stephanie L. Servetas,et al.  Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis , 2018, Microbiology and Molecular Biology Reviews.

[23]  L. Modolo,et al.  In vitro inhibition of Helicobacter pylori and interaction studies of lichen natural products with jack bean urease , 2018 .

[24]  E. El-Omar,et al.  Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. , 2017, The lancet. Gastroenterology & hepatology.

[25]  A. Axon,et al.  Epidemiology of Helicobacter pylori infection , 2017, Helicobacter.

[26]  WHO PUBLISHES LIST OF BACTERIA FOR WHICH NEW ANTIBIOTICS ARE URGENTLY NEEDED , 2017, Saudi Medical Journal.

[27]  W. Chey,et al.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection , 2017, The American Journal of Gastroenterology.

[28]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[29]  D. Taramelli,et al.  In vitro activity of artemisone and artemisinin derivatives against extracellular and intracellular Helicobacter pylori. , 2016, International journal of antimicrobial agents.

[30]  R. Hunt,et al.  The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. , 2016, Gastroenterology.

[31]  Jianhui Xie,et al.  (-)-Patchouli alcohol protects against Helicobacter pylori urease-induced apoptosis, oxidative stress and inflammatory response in human gastric epithelial cells. , 2016, International immunopharmacology.

[32]  Zongru Guo.  Artemisinin anti-malarial drugs in China , 2016, Acta pharmaceutica Sinica. B.

[33]  N. Stollman.  Helicobacter pylori Infection in the Era of Antibiotic Resistance. , 2016, Gastroenterology & hepatology.

[34]  Jason Y. Park,et al.  Review article: the global emergence of Helicobacter pylori antibiotic resistance , 2015, Alimentary pharmacology & therapeutics.

[35]  G. Mincione,et al.  Helicobacter pylori ATCC 43629/NCTC 11639 Outer Membrane Vesicles (OMVs) from Biofilm and Planktonic Phase Associated with Extracellular DNA (eDNA) , 2015, Front. Microbiol..

[36]  Joachim Müller,et al.  In vitro effects of new artemisinin derivatives in Neospora caninum-infected human fibroblasts. , 2015, International journal of antimicrobial agents.

[37]  H. Yonezawa,et al.  Biofilm Formation by Helicobacter pylori and Its Involvement for Antibiotic Resistance , 2015, BioMed research international.

[38]  S. Parapini,et al.  Bioactive compounds of Crocus sativus L. and their semi-synthetic derivatives as promising anti-Helicobacter pylori, anti-malarial and anti-leishmanial agents , 2015, Journal of enzyme inhibition and medicinal chemistry.

[39]  C. Doern,et al.  When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing , 2014, Journal of Clinical Microbiology.

[40]  K. Ochiai,et al.  Impact of Helicobacter pylori Biofilm Formation on Clarithromycin Susceptibility and Generation of Resistance Mutations , 2013, PloS one.

[41]  P. K. Das,et al.  Anti-Helicobacter pylori Potential of Artemisinin and Its Derivatives , 2012, Antimicrobial Agents and Chemotherapy.

[42]  B. Ho,et al.  Proteomannans in Biofilm of Helicobacter pylori ATCC 43504 , 2011, Helicobacter.

[43]  A. Aromaa,et al.  Gastric cancers in Finnish patients after cure of Helicobacter pylori infection: A cohort study , 2011, International journal of cancer.

[44]  R. Hunt,et al.  World Gastroenterology Organisation Global Guideline: Helicobacter pylori in Developing Countries , 2011, Journal of digestive diseases.

[45]  P. Malfertheiner,et al.  Helicobacter pylori in developing countries , 2010 .

[46]  B. Tekwani,et al.  Antiprotozoal, anticancer and antimicrobial activities of dihydroartemisinin acetal dimers and monomers. , 2009, Bioorganic & medicinal chemistry.

[47]  David A. Fidock,et al.  Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.

[48]  P. Alonso,et al.  New medicines to improve control and contribute to the eradication of malaria. , 2009, Nature reviews. Drug discovery.

[49]  L. Pelzer,et al.  Antimicrobial activity of Artemisia douglasiana and dehydroleucodine against Helicobacter pylori. , 2009, Journal of ethnopharmacology.

[50]  R. Bye,et al.  Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders. , 2009, Journal of ethnopharmacology.

[51]  G. Russello,et al.  Antimicrobial Susceptibility Testing of Helicobacter pylori Determined by Microdilution Method Using a New Medium , 2009, Current Microbiology.

[52]  A. Cook,et al.  The epidemiology of Helicobacter pylori infection in African refugee children resettled in Australia , 2008, The Medical journal of Australia.

[53]  Clinical,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .

[54]  C. Sugawa,et al.  Identification of Helicobacter pylori biofilms in human gastric mucosa , 2006, Journal of Gastrointestinal Surgery.

[55]  L. Gerena,et al.  Convenient Access Both to Highly Antimalaria‐Active 10‐Arylaminoartemisinins, and to 10‐Alkyl Ethers Including Artemether, Arteether, and Artelinate , 2005, Chembiochem : a European journal of chemical biology.

[56]  Toru Tanaka,et al.  Urease inhibitory activity of simple α,β-unsaturated ketones , 2003 .

[57]  O. Berg,et al.  Mutation frequency and biological cost of antibiotic resistance in Helicobacter pylori , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. M. Smith,et al.  Free recombination within Helicobacter pylori. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  H. Espejo,et al.  [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[60]  Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. , 1994, IARC monographs on the evaluation of carcinogenic risks to humans.

[61]  W. J. Novick.  Development of in vitro susceptibility testing criteria and quality control parameters , 1989 .

[62]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China. , 1985, Science.

[63]  D. L. Klayman,et al.  Qinghaosu (artemisinin): an antimalarial drug from China , 1985 .

[64]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[65]  L. Turnberg,et al.  Demonstration of a pH gradient across the mucus layer on the surface of human gastric mucosa in vitro. , 1982, Gut.

[66]  San José,et al.  Final Report and Recommendations , 1971, PS: Political Science & Politics.